Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,240.00

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price hoisted by equities research analysts at Royal Bank of Canada from $1,232.00 to $1,240.00 in a research report issued on Friday, Benzinga reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective would suggest a potential upside of 14.58% from the stock’s previous close.

A number of other research firms also recently weighed in on REGN. JPMorgan Chase & Co. lifted their price objective on Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday. UBS Group lifted their price objective on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the company a “buy” rating in a report on Wednesday, April 17th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a report on Thursday, June 27th. Morgan Stanley decreased their price objective on Regeneron Pharmaceuticals from $1,183.00 to $1,182.00 and set an “overweight” rating on the stock in a report on Thursday, July 11th. Finally, Wells Fargo & Company lifted their price objective on Regeneron Pharmaceuticals from $1,125.00 to $1,200.00 and gave the company an “overweight” rating in a report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,097.05.

Regeneron Pharmaceuticals Stock Performance

REGN stock traded down $10.95 during trading on Friday, reaching $1,082.19. 629,873 shares of the stock were exchanged, compared to its average volume of 470,399. Regeneron Pharmaceuticals has a twelve month low of $759.15 and a twelve month high of $1,115.00. The company has a market capitalization of $119.25 billion, a P/E ratio of 31.97, a price-to-earnings-growth ratio of 2.31 and a beta of 0.13. The stock has a 50 day simple moving average of $1,041.48 and a 200-day simple moving average of $981.44. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The firm had revenue of $3.15 billion for the quarter, compared to analyst estimates of $3.19 billion. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 37.38 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,047.11, for a total transaction of $1,190,564.07. Following the completion of the sale, the executive vice president now owns 12,931 shares in the company, valued at approximately $13,540,179.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Leonard S. Schleifer sold 22,830 shares of the business’s stock in a transaction on Friday, May 17th. The shares were sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the transaction, the chief executive officer now directly owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold 65,074 shares of company stock worth $64,546,123 in the last quarter. Insiders own 7.48% of the company’s stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. West Paces Advisors Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 23 shares during the period. Stephens Consulting LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $26,000. Crewe Advisors LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter worth $28,000. MCF Advisors LLC boosted its stake in Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 12 shares during the period. Finally, Lynx Investment Advisory acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter worth $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.